Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 25581108)

Published in Int J Stroke on January 12, 2015

Authors

Kazunori Toyoda1, Shoji Arihiro1, Kenichi Todo2, Hiroshi Yamagami3, Kazumi Kimura4, Eisuke Furui5, Tadashi Terasaki6, Yoshiaki Shiokawa7, Kenji Kamiyama8, Shunya Takizawa9, Satoshi Okuda10, Yasushi Okada11, Tomoaki Kameda12, Yoshinari Nagakane13, Yasuhiro Hasegawa14, Hiroshi Mochizuki15, Yasuhiro Ito16, Takahiro Nakashima17, Kazuhiro Takamatsu18, Kazutoshi Nishiyama19, Kazuomi Kario20, Shoichiro Sato1, Masatoshi Koga1, SAMURAI Study Investigators

Author Affiliations

1: Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
2: Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Hyōgo, Japan.
3: Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
4: Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan.
5: Department of Stroke Neurology, Kohnan Hospital, Sendai, Miyagi, Japan.
6: Department of Neurology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan.
7: Departments of Neurosurgery and Stroke Center, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
8: Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan.
9: Department of Neurology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
10: Department of Neurology, NHO Nagoya Medical Center, Nagoya, Chūbu, Japan.
11: Department of Neurology and Cerebrovascular Medicine, NHO Kyushu Medical Center, Fukuoka, Fukuoka, Japan.
12: Division of Neurology, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
13: Department of Neurology, Kyoto Second Red Cross Hospital, Kyoto, Honshu, Japan.
14: Department of Neurology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
15: Department of Neurology, South Miyagi Medical Center, Ogawara, Miyagi, Japan.
16: Department of Neurology, TOYOTA Memorial Hospital, Toyota, Aichi, Japan.
17: Department of Cerebrovascular Medicine, NHO Kagoshima Medical Center, Kagoshima, Kagoshima, Japan.
18: Department of Neurology, Brain Attack Center Ota Memorial Hospital, Fukuyama, Hiroshima, Japan.
19: Department of Neurology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
20: Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.

Associated clinical trials:

SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) (SAMURAI-NVAF) | NCT01581502

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 7.48

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 4.56

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52

Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol (2014) 2.30

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol (2012) 1.99

Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J (2014) 1.30

Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost (2014) 1.13

Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS One (2014) 0.86

Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci (2013) 0.80

Articles by these authors

Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke (2013) 2.23

Deficiency of myeloperoxidase increases infarct volume and nitrotyrosine formation in mouse brain. J Cereb Blood Flow Metab (2002) 1.03

Cerebral small vessel disease and chronic kidney disease. J Stroke (2015) 0.89

Early-onset dystonia after supplementary motor area infarction. J Stroke Cerebrovasc Dis (2014) 0.81

Epidemiology and registry studies of stroke in Japan. J Stroke (2013) 0.81

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy without anterior temporal pole involvement: a case report. J Stroke Cerebrovasc Dis (2013) 0.81

Intravenous recombinant tissue plasminogen activator therapy for stroke patients receiving maintenance hemodialysis: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Eur Neurol (2011) 0.79

Factors Associated with Early Hospital Arrival in Patients with Acute Ischemic Stroke. J Stroke (2015) 0.78

Reperfusion enhances nitrotyrosine formation in rat focal cerebral ischemia. J Stroke Cerebrovasc Dis (2007) 0.77

Early Stroke Risk after Transient Ischemic Attack in Patients without Large-Artery Disease or Atrial Fibrillation. J Stroke Cerebrovasc Dis (2015) 0.76

Blood glucose levels during the initial 72 h and 3-month functional outcomes in acute intracerebral hemorrhage: the SAMURAI-ICH study. J Neurol Sci (2015) 0.76

Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms. Am J Obstet Gynecol (2016) 0.76

Response to Letter Regarding Article, "Acute Reperfusion Therapy and Stroke Care in Asia After Successful Endovascular Trials". Stroke (2015) 0.75

Percutaneous Transluminal Angioplasty Improved Posterior Reversible Encephalopathy Syndrome due to Renovascular Hypertension. J Stroke Cerebrovasc Dis (2015) 0.75

Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial. J Stroke Cerebrovasc Dis (2015) 0.75

Stroke education using an animated cartoon and a manga for junior high school students. J Stroke Cerebrovasc Dis (2014) 0.75

Continuous antihypertensive therapy throughout the initial 24 hours of intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke (2014) 0.75

Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke (2016) 0.75

Development of Interstitial Lung Disease after Initiation of Apixaban Anticoagulation Therapy. J Stroke Cerebrovasc Dis (2016) 0.75

Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation. Stroke (2016) 0.75

Ipsilateral hemiparesis in lateral medullary infarction: Clinical investigation of the lesion location on magnetic resonance imaging. J Neurol Sci (2016) 0.75

What are the next breakthroughs in the management of acute intracerebral hemorrhage? Int J Stroke (2016) 0.75

Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study. Int J Hematol (2017) 0.75

Slowly progressive Lemierre's syndrome with orbital pain and exophthalmos. J Infect Chemother (2015) 0.75

Novel brain computed tomography perfusion for cerebral malperfusion secondary to acute type A aortic dissection. Interact Cardiovasc Thorac Surg (2022) 0.75

Risk factors for post-stroke seizure recurrence after the first episode. Seizure (2017) 0.75

The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol. J Stroke Cerebrovasc Dis (2016) 0.75

Optimal Peak Systolic Velocity Thresholds for Predicting Internal Carotid Artery Stenosis Greater than or Equal to 50%, 60%, 70%, and 80. J Stroke Cerebrovasc Dis (2016) 0.75

Neurologic improvement without angiographic improvement after antithyroid therapy in a patient with Moyamoya syndrome. J Stroke Cerebrovasc Dis (2013) 0.75